Archives
-
Nystatin (Fungicidin): Workflow & Assay Guide
2026-09-08
Nystatin (Fungicidin) combines a defined ergosterol-targeting mechanism with practical value in Candida susceptibility, adhesion, and membrane-integrity studies. This guide also shows how to use Nystatin as a specificity control in reovirus entry experiments without confusing antifungal activity with antiviral efficacy.
-
Intranasal Epinephrine in Dogs: PK and Heart Rate
2026-09-08
The reference study evaluated intranasal epinephrine as a rapid, needle-free alternative to intramuscular delivery in dogs, combining dose-ranging pharmacokinetics with heart-rate measurements. Its most important finding was that intranasal dosing produced rapid systemic exposure and comparable overall exposure at selected dose pairs, while producing smaller heart-rate increases than intramuscular administration.
-
Pemetrexed Workflows for Translational Cancer Research
2026-09-07
Build reproducible Pemetrexed assays that connect folate-pathway inhibition with DNA-repair phenotypes in tumor models. This workflow combines dose-response profiling, biomarker-aware controls, and practical troubleshooting for non-small cell lung carcinoma research and malignant mesothelioma models.
-
How p38α Inhibitors Tune Dephosphorylation
2026-09-07
A bioRxiv preprint reports that selected p38α MAP kinase inhibitors can both inhibit catalysis and accelerate WIP1-mediated removal of the activation-loop phosphate. Biochemical experiments and X-ray structures connect this dual action to an inhibitor-stabilized activation-loop conformation that exposes phospho-threonine, suggesting a route toward greater kinase-inhibitor specificity.
-
Ozone, Efferocytosis, and Neuropathic Pain
2026-09-05
A 2024 Frontiers in Immunology study identifies macrophage efferocytosis as a mechanistically actionable process in neuropathic pain. In a chronic constriction injury model, ozone enhanced AMPK/Gas6-MerTK signaling, increased apoptotic-cell clearance, elevated SOCS3, and reduced inflammatory mediators, linking defective corpse removal with pain hypersensitivity.
-
FAST for Food-Grade Nutraceutical Nanoparticles
2026-09-04
The 2026 reference study presents Facilitated Self-Assembling Technology (FAST) as a surfactant-free, food-grade route for forming stable nanoparticles from poorly soluble nutraceuticals. Its findings suggest that FAST can improve formulation stability and support scalable oral delivery, although full product-specific regulatory and bioavailability validation remains necessary.
-
FXR Phase Separation Clusters Coronavirus Organelles
2026-09-04
Li et al. (2024) identify fragile X–related proteins as host factors that organize β-coronavirus replication organelles through liquid–liquid phase separation. The study connects FXR condensates, double-membrane vesicle clustering, local translation, and SARS-CoV-2 replication, providing a mechanistic framework for interpreting replication-organelle architecture.
-
Vancomycin and the Gut–Immune Axis in AR Models
2026-09-03
Vancomycin is examined here as a controlled microbiome perturbation tool rather than only a conventional glycopeptide antibiotic. The article connects peptidoglycan precursor binding with allergic-rhinitis assay design, integrating microbial, metabolic, and immune readouts while defining the limits of current evidence.
-
25-Hydroxycholesterol Reprograms Immunosuppressive TAMs
2026-09-03
Xiao et al. identify CH25H and lysosomal 25-hydroxycholesterol as an immunometabolic checkpoint that connects cholesterol handling to AMPKα–STAT6 signaling in tumor-associated macrophages. The study also shows that targeting CH25H can increase T-cell activity and improve anti-tumor responses, including in combination with anti-PD-1 therapy.
-
DAPI Workflows for Nuclear Imaging and Viability
2026-09-02
DAPI Solution (1 mg/mL) supports high-contrast nuclear imaging, membrane-compromise readouts, and flow-based DNA staining in workflows ranging from fixed-cell microscopy to tumor-microenvironment studies. This guide connects practical staining decisions with the PAD4–H3cit–NETs findings reported in a recent cancer study, while clarifying what DAPI can—and cannot—prove about apoptosis or therapeutic response.
-
Thymoquinone C5035: Reliable Cell Assay Workflows
2026-09-02
A scenario-driven guide to using Thymoquinone (SKU C5035) in cell viability, proliferation, and cytotoxicity workflows. It connects formulation, dosing, controls, interpretation, and vendor selection with mechanistic and cardiotoxicity evidence.
-
Rotenone: From Complex I Stress to PD Assays
2026-09-01
Rotenone is a mitochondrial Complex I inhibitor that can connect bioenergetic disruption with neuronal injury in Parkinson’s disease model research. This guide focuses on experimental interpretation, assay design, and insights from circ-Pank1 research rather than repeating a general mechanism overview.
-
Tofacitinib and RA Macrophage Immunometabolism
2026-09-01
Tofacitinib (CP-690550, Tasocitinib) is more than a general anti-inflammatory tool. Emerging evidence shows that it can interrupt GM-CSF-associated STAT5 signaling, reshape inflammatory macrophage states, and restore mitochondrial organization in rheumatoid arthritis models. This thought-leadership analysis translates those findings into practical assay design, translational biomarker strategy, and a more precise view of JAK pathway intervention.
-
Toremifene: A Mechanism-First Research Framework
2026-08-31
Toremifene is a selective estrogen-receptor modulator for rigorous prostate cancer research. This article presents a mechanism-first framework that connects estrogen receptor context, calcium-dependent metastasis biology, and assay design without overstating the current evidence.
-
Cyclic Pifithrin-α Hydrobromide in Causal Assays
2026-08-31
Cyclic Pifithrin-α hydrobromide is a p53 inhibitor for separating p53-dependent stress responses from broader inflammatory signaling. This article develops an assay framework linking DNA-damage biology with the Ca2+-CGRP/SP-Piezo2 findings in trigeminal pain research while maintaining appropriate evidence boundaries.